Stock analysis, AI verdict, fundamentals & technical signals
Rating: HOLD
Price: $51.78 Analyst target: $59.71 Upside: 15.31%
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.